Trump Expands Tariffs on Pharmaceuticals and Metals One Year After Liberation Day
This story raises questions about governance, accountability, and American values.
The mainstream coverage treats Trump’s new tariffs as political theater, as if “free trade” is a moral good regardless of who gets hollowed out along the way. That framing skips over the point: dependence is not efficiency when it leaves you exposed. Pharmaceuticals are not sneakers.
New Republican Times Editorial Board
One year after his sweeping Liberation Day tariff announcements, President Donald Trump has introduced a new wave of trade measures targeting pharmaceutical imports and restructuring duties on steel, aluminum, and copper.
Original source:
Read at EconotimesHow We See It
New Republican Times Editorial Board
The mainstream coverage treats Trump’s new tariffs as political theater, as if “free trade” is a moral good regardless of who gets hollowed out along the way. That framing skips over the point: dependence is not efficiency when it leaves you exposed.
Pharmaceuticals are not sneakers. Metals are not a luxury. A country that cannot reliably make critical drugs, steel, aluminum, and copper is outsourcing its resilience. National security supply chains matter, and so does strategic self-reliance when rivals can choke access or spike prices overnight.
Tariffs are blunt, and they should be paired with faster permitting and clear rules so domestic investment follows. But the real choice is between economic sovereignty and a system that rewards offshoring while calling it “market discipline.”
The principle at stake is simple: public trust requires a government that plans for shocks, not one that hopes global commerce stays polite.
Commentary written with AI assistance by the New Republican Times Editorial Board.